Methods of treatment of breast cancer
AssigneeAstraZeneca AB
InventorsJustin Pieter Oliver LINDEMANN, Teresa Caroline Maria Klinowska, Susan Mary GALBRAITH, Christopher Jon MORROW
Life of this patent
Estimating the term…
Abstract
The present specification relates methods of treatment of hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2−), metastatic or loco-regionally recurrent breast cancer, comprising administering a next generation selective estrogen receptor degrader (ngSERD), for example camizestrant, to a patient suffering from such cancer, characterised in that the cancer has recurred or progressed following at least one prior line of endocrine therapy.
Claims22
A method of treatment of HR+, HER2−, metastatic or loco-regionally recurrent breast cancer, comprising administering a therapeutically effective amount of camizestrant or a pharmaceutically acceptable salt thereof to a patient in need thereof wherein the cancer has recurred or progressed following at least one prior line of endocrine therapy;
- and wherein the camizestrant or a pharmaceutically acceptable salt thereof is orally administered once daily at a dose of 75 mg.
(canceled)
(canceled)
(canceled)
A method of treatment of HR+, HER2−, metastatic or loco-regionally recurrent breast cancer, comprising administering a therapeutically effective amount of camizestrant or a pharmaceutically acceptable salt thereof to a patient in need thereof, wherein the cancer has recurred or progressed following at least one prior line of endocrine therapy, and wherein:
- a) the method results in an improvement in the median time to disease progression of at least 3.5 months relative to that observed with fulvestrant treatment;
- and/or
- b) the method results in a hazard ratio for camizestrant treatment relative to fulvestrant treatment of less than or equal to 0.67;
- and/or
- c) the method results in a median time to disease progression of at least 7 months.
(canceled)
A method of treatment of HR+, human epidermal growth factor receptor 2 negative HER2−, metastatic or loco-regionally recurrent breast cancer, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising camizestrant or a pharmaceutically acceptable salt thereof to a patient in need thereof, wherein the cancer has recurred or progressed following at least one prior line of endocrine therapy, and wherein:
- a) the method results in an improvement in the median time to disease progression of at least 3.5 months relative to that observed with fulvestrant treatment;
- and/or
- b) the method results in a hazard ratio for camizestrant treatment relative to fulvestrant treatment of less than or equal to 0.67;
- and/or
- c) the method result in a median time to disease progression of at least 7 months.
(canceled)
Dependencies are inferred from the claim text.